CN111840544A - Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype - Google Patents
Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype Download PDFInfo
- Publication number
- CN111840544A CN111840544A CN201910356158.5A CN201910356158A CN111840544A CN 111840544 A CN111840544 A CN 111840544A CN 201910356158 A CN201910356158 A CN 201910356158A CN 111840544 A CN111840544 A CN 111840544A
- Authority
- CN
- China
- Prior art keywords
- antibody
- defucose
- cancer
- glycosyl
- glycosyl structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The application discloses an application of a defucose anti-HER 2 antibody in a cancer patient carrying Fc gamma R2A131R genotype. The defucose anti-HER 2 antibody is produced by a cell that knocks down the FUT8 gene; the amino acid sequence of the light chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the heavy chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 3. The defucose anti-HER 2 antibody has better ADCC activity than that of a defucose anti-HER 2 antibody no matter whether the Fc gamma R2A genotype is H/H type, or H/R type, or R/R type, and particularly has obvious advantages of ADCC of the defucose anti-HER 2 antibody when the Fc gamma R2A genotype is R/R type or H/R type.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to application of a defucose anti-HER 2 antibody in a cancer patient carrying Fc gamma R2A131R/R or 131H/R allelic genes.
Background
The world health organization reports show that global cancer cases will present a rapidly growing situation, from 1400 million people in 2012, increasing year by year to 1900 million people in 2025, and up to 2400 million people by 2035. The developing countries in africa, asia and central and south america have the most severe forms of cancer. In 2012, there are 1400 new cancer cases worldwide and 820 deaths.
Cancer morbidity and mortality in china are rising all the time, have become the main cause of death since 2010, and have become a major public health problem in china. According to the Chinese cancer statistical report in 2015, 4,292,000 new cancer cases and 2,814,000 cancer deaths are predicted in 2015, and the incidence and mortality of lung cancer are the highest. The morbidity and mortality of gastric, esophageal and liver cancers is also high.
HER2 is a member of the epidermal growth factor receptor family. The human HER2 gene maps to chromosome 17 (17q21-22) and expresses a single-chain transmembrane glycoprotein with a molecular weight of 185,000 daltons. The structure of HER2 is highly homologous to the Epidermal Growth Factor Receptor (EGFR), which is a member of the EGFR family. This family also includes HER1(ErbBl), HER3(ErbB3) and HER4(ErbB4), which act in dimeric or oligomeric forms. HER2 receptor dimerization can induce tyrosine kinase activation, so that the C-terminal tyrosine residue of the receptor is autophosphorylated, an intracellular signal cascade reaction is excited, the activation of downstream signal molecules is promoted, and various biological effects such as cell growth, differentiation, transfer, adhesion and the like are caused; when HER2 is overexpressed, it can cause uncontrolled cell growth and proliferation, malignant transformation, and tumor infiltration and metastasis. HER2 is overexpressed in a variety of tumor cells, including breast, ovarian, prostate, lung, stomach, esophageal, colon, and the like. And most studies suggest that HER2 expression is correlated with tumor stage.
Herceptin, the main component of which is Trastuzumab (Trastuzumab), is a targeted drug against HER2 developed by Genentech, Inc. in the United states. It is a human recombinant monoclonal antibody (MAb) directed against the Ectodomain (EDC) of HER2/neu protein, in which the murine complementarity determining region (i.e., clone 4D5) is inserted into the human IgGl framework. Herceptin was approved in 1998 in the united states for HER 2-overexpressed breast cancers, including metastatic breast cancer and metastatic gastric cancer. Since the market, the single-drug objective response rate of herceptin was 15-26%.
One important mechanism by which herceptin acts is by utilizing the constant domains (Fc) of its antibodies to trigger antibody-dependent cellular (mediated) cytotoxicity (ADCC) effects and Fc-mediated immunopotentiation by binding to leukocyte receptors (fcyr). Thus, the binding of an antibody to a receptor directly affects the potency of the antibody. Two factors influence the ability of Fc to bind Fc γ R: the Fc gamma R has certain difference due to the polymorphism of the Fc gamma R; secondly, the sugar structure mode of the Fc region of the antibody shows that the antibodies with different glycosylation characteristics can show different ADCC effects, so that the optimized glycosylation of the Fc segment of the antibody can achieve the effect of improving the ADCC effect of the antibody.
ADCC results in the specific lysis of antigen-positive tumor cells. Compared with the effect of second-line afatinib + vinorelbine and herceptin + vinorelbine after the auxiliary or first-line high fucose anti-HER 2 antibody of a HER2 positive breast cancer patient, namely the herceptin develops, the effect of the afatinib group is obviously inferior to that of the herceptin group. Small molecule Tyrosine Kinase Inhibitors (TKIs), such as afatinib, are highly potent and irreversible inhibitors against HER proteins with full kinase activity (EGFR, HER2, HER4), while afatinib blocks all heterohomodimers of the HER family, herceptin still shows strong advantages over such potent TKIs, this clinical study strongly supports the in vivo role of herceptin, i.e. the high fucose anti-HER 2 antibody, probably more dependent on its ADCC effect.
Fc γ R plays an important role in immune regulation, mediating ADCC, endocytosis, phagocytosis, and release of inflammatory factors and antigen presentation. Fc γ R is classified into 3 types: fc γ R1(CD64), Fc γ R2(CD32), and Fc γ R (CD 16). Specific genes, each located in the same region of the long arm of the chromosome, encode several different genotypes, including Fc γ R1A, Fc γ R1B, Fc γ R1C, Fc γ R2A, Fc γ R2B1, Fc γ R2B2, Fc γ R2B3, Fc γ R2C, Fc γ R3A, and Fc γ R3B. Single Nucleotide Polymorphism (SNP), i.e., a polymorphism in a nucleic acid sequence due to a change in a single nucleotide base, is generally considered to be distinguished from point mutations in that SNPs occur at a frequency of more than 1%. SNPs in the coding region of a gene often result in amino acid changes that in turn affect the function of the protein. The histidine to arginine mutation at Fc γ R2A 131 site (H131R) affected the antibody and its binding.
Disclosure of Invention
The removal of fucose from the glycosylation site of the Fc region of the high fucose anti-HER 2 antibody increases the ADCC activity due to the increased affinity of the Fc γ R2A molecule on the cell membrane of the antibody and some effector cells such as NK cells, macrophages, etc. The invention finds that the affinity of the defucose anti-HER 2 antibody for Fc gamma R2A131R genotype is particularly obviously enhanced. In order to improve the tumor treatment effect and/or expand the tumor application range, the invention aims to provide the application of the defucose anti-HER 2 antibody in a cancer patient carrying Fc gamma R2A131 genotype.
The defucose anti-HER 2 antibody is produced by a cell that knocks down the FUT8 gene; the amino acid sequence of the light chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 1, and the nucleotide sequence is shown as SEQ ID NO. 2; the amino acid sequence of the heavy chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 3, and the nucleotide sequence is shown as SEQ ID NO. 4.
Further, a CH2 domain is included; the amount of fucose in the CH2 domain is zero.
Further, a sugar-based structure is included, the sugar-based structure including a first sugar-based structure consisting of 3 six-carbon sugars and 4N-acetylhexosamine; the proportion of the first glycosyl structure in the glycosyl structure is 60% -95%; the six-carbon sugar comprises one or more of galactose, mannose and glucose; the N-acetylhexosamine includes N-acetylgalactosamine and/or N-acetylglucosamine.
Further, the six carbon sugar is mannose; the N-acetylhexosamine is N-acetylglucosamine.
Further, the glycosyl structure further comprises a second glycosyl structure, a third glycosyl structure, a fourth glycosyl structure, a fifth glycosyl structure and/or a sixth glycosyl structure; the glycosyl composition of the second glycosyl structure, the third glycosyl structure, the fourth glycosyl structure, the fifth glycosyl structure and the sixth glycosyl structure and the proportion of the glycosyl structures are shown in the following table:
glycosyl structure | Glycosyl composition | Ratio of |
Second glycosyl structure | 4 six carbon sugars and 4N-acetylhexosamine | 2%-15% |
A third glycosyl structure | 3 six carbon sugars and 3N-acetylhexosamine | 0-10% |
Fourth glycosyl structure | 5 six carbon sugars and 2N-acetylhexosamine | 0-10% |
Fifth glycosyl structure | 5 six carbon sugars and 4N-acetylhexosamine | 0-10% |
Sixth glycosyl structure | 3 six carbon sugars and 5N-acetylhexosamine | 0-10% |
Further, sugar chains corresponding to the first, second, third, fourth, fifth and sixth sugar structures, respectively, are shown in the following table:
wherein circles in the sugar chain represent the six-carbon sugar; black squares represent the N-acetylglucosamine; black hexagons represent galactose; black circles indicate mannose.
Further, the cell is a CHO cell, and the knocking-out is realized by knocking out a gene responsible for encoding fucose, namely, a FUT8 gene in the CHO cell by using CRISPR cas9 gene editing technology.
Further, the patient is HER2 positive; the cancer comprises one or more of breast cancer, esophageal cancer, gastric cancer, lung cancer, bronchial cancer, pancreatic cancer, colon cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, and head and neck cancer.
Further, the medicament is for HER2 positive metastatic cancer.
Further, the medicament is used for the metastasis of HER2 positive malignant tumor, and the metastasis of HER2 positive malignant tumor comprises one or more of skin metastasis, visceral metastasis and lymphatic metastasis.
The invention has the following beneficial effects:
1. the affinity of the defucose anti-HER 2 antibody and the extracellular region ECD of HER2 was comparable to the affinity of the high fucose anti-HER 2 antibody and the extracellular region ECD of HER 2.
2. The affinity of the defucose anti-HER 2 antibody and the Fc gamma R2A131H genotype protein is 10 times that of the high fucose anti-HER 2 antibody, and the affinity of the defucose anti-HER 2 antibody and the Fc gamma R2A131R genotype protein is 16 times that of the high fucose anti-HER 2 antibody, and the increase of the affinity is the basis for the exertion of higher ADCC effect in vivo.
3. The genotype of the defucose anti-HER 2 antibody in a HER2 positive patient Fc gamma R2A is Fc gamma R2A131R/R or Fc gamma R2A131H/R, which shows stronger tumor killing effect than the high fucose anti-HER 2 antibody.
The defucose anti-HER 2 antibody is a specific glycosylation optimized anti-HER 2 antibody, the ADCC anti-tumor effect of the herceptin antibody approved for treating HER2 over-expressed breast cancer and gastric cancer is enhanced by 10-50 times, so that more excellent anti-tumor effect can be achieved, better effectiveness and lower drug resistance are generated on HER2 positive tumors, and the genotype of HER2 positive cancer patient Fc gamma R2A is Fc gamma R2A131R/R or Fc gamma R2A 131H/R.
Detailed Description
The protection of the present invention is not limited to the following examples. Variations and advantages that may occur to those skilled in the art may be incorporated into the invention without departing from the spirit and scope of the inventive concept, and the scope of the appended claims is intended to be protected. The procedures, conditions, reagents, experimental methods and the like for carrying out the present invention are general knowledge and common general knowledge in the art except for the contents specifically mentioned below, and the present invention is not particularly limited.
The defucose anti-HER 2 antibody of the present invention has the same amino acid sequence as herceptin, but is expressed in CHO cells in which the FUT8 gene is knocked out, and thus is afucose trastuzumab, and is represented by "FUC-trastuzumab".
The control high fucose anti-HER 2 antibody used in the present invention is trastuzumab, the main component of herceptin, and is denoted by "FUC + trastuzumab".
CHO-S cells in the present invention were obtained from Invitrogen, and all other cells were purchased from ATCC (American type culture Collection). The relevant reagents are commercially available.
The defucose anti-HER 2 antibody and the high fucose anti-HER 2 antibody of the present invention are identical to those of the prior patent 2016111168043.
Example 1 comparison of the affinity of the defucose anti-HER 2 and high fucose anti-HER 2 antibodies to the receptors human Fc γ R2A131R/R genotype receptor protein and Fc γ R2A131R/R genotype receptor protein
The experiment was performed on a Biacore T200 mobile phase PBS buffer (8.0 g NaCl, 0.2g KCl, KH)2PO40.24g,Na2HPO4×12H2O3.628 g in 800ml of distilled water, pH 7.4 adjusted with hydrochloric acid, and volume of distilled water to 1000ml), all the samples were dissolved in the above PBS buffer.
The defucose anti-HER 2 antibody and the high fucose anti-HER 2 antibody were immobilized by amino coupling on a CM5 sensor chip at a flow rate of 10ul/min, and the surface of the CM5 chip was activated with an equal volume of mixed solution of EDC at a concentration of 0.1mol/L and NHS at a concentration of 0.1 mol/L.
Fc γ R2a131R or Fc γ R2a131H employ multi-cycle kinetics. Respectively preparing Fc gamma R2A131R or Fc gamma R2A131H with different concentrations, setting the flow rate of an experiment to be 30ul/min, the sample injection time to be 120s, adopting a 5M NaCl regeneration solution, and the dissociation time to be 30 s. The results of the experiment are shown in table 1.
TABLE 1 affinity of defucose anti-HER 2 and high fucose anti-HER 2 antibodies to different genotypes Fc gamma R2A131H/R, respectively
From the experimental results, we can see that: the affinity of the defucose anti-HER 2 antibody and the Fc γ R2a131R genotype protein was 16 times that of the high fucose anti-HER 2 antibody, and the affinity of the defucose anti-HER 2 antibody and the Fc γ R2a131H genotype protein was 10 times that of the high fucose anti-HER 2 antibody. This increase in affinity is the basis for the development of a higher ADCC effect in vivo.
Example 2 comparison of ADCC Activity of different genotype donors on SK-BR-3 cells mediated by a defucose anti-HER 2 antibody and a high fucose anti-HER 2 antibody
The PBMC source respectively selects three donors of Fc gamma R2A131(H/H), Fc gamma R2A131(H/R) and Fc gamma R2A131 (R/R).
The technical method comprises the following steps:
HER2 positivity differentiated in RPMI 1640 medium containing 2% Fetal Bovine Serum (FBS)The tumor cell of (2) to (10)4The method comprises the steps of inoculating a well to a 96-well plate, adding defucose anti-HER 2 antibody and high fucose anti-HER 2 antibody with different concentrations, placing the well in an incubator at 37 ℃ for half an hour, adding freshly separated human Peripheral Blood Mononuclear Cells (PBMC) according to the ratio of 20:1, namely adding 20 ten thousand PBMC into each well, placing the well in the incubator at 37 ℃ for 4 hours, detecting the activity of lactate dehydrogenase (lactate dehydrogenase) by using a Roche cytotoxicity detection kit, and setting three multiple wells for all detection. Finally, the absorbance at OD490 was measured by reading on a microplate reader. The maximum release amount was determined by adding triton x100, the spontaneous release amount was determined by adding only target cells (cell lines shown in table 2) and effector cells (PBMCs) without adding antibodies, and the minimum release amount was determined by adding only target cells, and the specific cytotoxicity was calculated as: cell lysis (%) (experimental group release-spontaneous release)/(maximum release-minimum release) × 100%. The results of the comparison are shown in Table 2.
TABLE 2 comparison of ADCC Activity of defucose anti-HER 2 and high fucose anti-HER 2 antibodies in SK-BR-3 tumor cells (PBMC of different genotype origin)
For donors with Fc γ R2A genotype 131(H/H) with ADCC effect on SK-BR-3 cells, the EC50 of the high fucose anti-HER 2 antibody was 3.3 times that of the defucose anti-HER 2 antibody; for donors with Fc γ R2A genotype 131(H/R) with ADCC effect on SK-BR-3 cells, the EC50 of the high fucose anti-HER 2 antibody was 13.3 times that of the defucose anti-HER 2 antibody; for donors with Fc γ R2A genotype 131(R/R) with ADCC effect on SK-BR-3 cells, the EC50 of the high fucose anti-HER 2 antibody was 32 times that of the defucose anti-HER 2 antibody.
According to example 2, in the tumor highly expressing HER2 molecule (IHC3+), since the activity of the defucose anti-HER 2 antibody is much greater than that of the high fucose anti-HER 2 antibody, it can also be applied to some tumor patients highly expressing HER2 molecule (IHC3+), but the Fc γ R2A genotype of these patients is H/R or R/R type, resulting in the tumor which has lower affinity of the high fucose anti-HER 2 antibody and NK effector cells and may not respond to the high fucose anti-HER 2 antibody.
In summary, the defucose anti-HER 2 antibody has better ADCC activity than the defucose anti-HER 2 antibody for no matter whether the Fc gamma R2A genotype is H/H type, or H/R type, or R/R type, and particularly has obvious advantages of ADCC of the defucose anti-HER 2 antibody for the FCR2A genotype is R/R type, or H/R type.
Sequence listing
<110> Shanghai Yao Biotechnology Ltd
<120> use of defucose anti-HER 2 antibody in patients with cancer bearing Fc gamma R2A131R genotype
<130>JH-CNP190437
<160>4
<170>PatentIn version 3.5
<210>1
<211>214
<212>PRT
<213> Artificial sequence
<400>1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210>2
<211>651
<212>DNA
<213> Artificial sequence
<400>2
atgggtgaca tccagatgac ccagtctccg tcttctctgt ctgcttctgt tggtgaccgt 60
gttaccatca cctgccgtgc ttctcaggac gttaacaccg ctgttgcttg gtaccagcag 120
aaaccgggta aagctccgaa actgctgatc tactctgctt ctttcctgta ctctggtgtt 180
ccgtctcgtt tctctggttc tcgttctggt accgacttca ccctgaccat ctcttctctg 240
cagccggaag acttcgctac ctactactgc cagcagcact acaccacccc gccgaccttc 300
ggtcagggta ccaaagttga aatcaaacgt accgttgctg ctccgtctgt tttcatcttc 360
ccgccgtctg acgaacagct gaaatctggt accgcttctg ttgtttgcct gctgaacaac 420
ttctacccgc gtgaagctaa agttcagtgg aaagttgaca acgctctgca gtctggtaac 480
tctcaggaat ctgttaccga acaggactct aaagactcta cctactctct gtcttctacc 540
ctgaccctgt ctaaagctga ctacgaaaaa cacaaagttt acgcttgcga agttacccac 600
cagggtctgt cttctccggt taccaaatct ttcaaccgtg gtgaatgcta a 651
<210>3
<211>450
<212>PRT
<213> Artificial sequence
<400>3
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr
20 25 30
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu GlyGly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly Lys
450
<210>4
<211>1359
<212>DNA
<213> Artificial sequence
<400>4
atgggtgaag ttcagctggt tgaatctggt ggtggtctgg ttcagccggg tggttctctg 60
cgtctgtctt gcgctgcttc tggtttcaac atcaaagaca cctacatcca ctgggttcgt 120
caggctccgg gtaaaggtct ggaatgggtt gctcgtatct acccgaccaa cggttacacc 180
cgttacgctg actctgttaa aggtcgtttc accatctctg ctgacacctc taaaaacacc 240
gcttacctgc agatgaactc tctgcgtgct gaagacaccg ctgtttacta ctgctctcgt 300
tggggtggtg acggtttcta cgctatggac tactggggtc agggtaccct ggttaccgtt 360
tcttctgctt ctaccaaagg tccgtctgtt ttcccgctgg ctccgtcttc taaatctacc 420
tctggtggta ccgctgctct gggttgcctg gttaaagact acttcccgga accggttacc 480
gtttcttgga actctggtgc tctgacctct ggtgttcaca ccttcccggc tgttctgcag 540
tcttctggtc tgtactctct gtcttctgtt gttaccgttc cgtcttcttc tctgggtacc 600
cagacctaca tctgcaacgt taaccacaaa ccgtctaaca ccaaagttga caaaaaagtt 660
gaaccgaaat cttgcgacaa aacgcacacg tgcccgcctt gcccggctcc ggaactgctg 720
ggtggcccga gcgtgtttct gttcccgccg aaaccgaaag acaccctgat gatctctcgt 780
accccggaag ttacctgcgt tgttgttgac gtttctcacg aagacccgga agttaaattc 840
aactggtacg ttgacggtgt tgaagttcac aacgctaaaa ccaaaccgcg tgaagaacag 900
tacaactcta cctaccgtgt tgtttctgtt ctgaccgttc tgcaccagga ctggctgaac 960
ggtaaagaat acaaatgcaa agtttctaac aaagctctgc cggctccgat cgaaaaaacc 1020
atctctaaag ctaaaggtca gccgcgtgaa ccgcaggttt acaccctgcc gccgtctcgt 1080
gaagaaatga ccaaaaacca ggtttctctg acctgcctgg ttaaaggttt ctacccgtct 1140
gacatcgctg ttgaatggga atctaacggt cagccggaaa acaactacaa aaccaccccg 1200
ccggttctgg actctgacgg ttctttcttc ctgtactcta aactgaccgt tgacaaatct 1260
cgttggcagc agggtaacgt tttctcttgc tctgttatgc acgaagctct gcacaaccac 1320
tacacccaga aatctctgtc tctgtctccg ggtaaataa 1359
Claims (10)
1. Use of a defucose anti-HER 2 antibody as an active ingredient in the manufacture of a medicament for treating a patient with a cancer having an Fc γ R2A131R genotype, said defucose anti-HER 2 antibody being produced by a cell in which an FUT8 gene is knocked out; the amino acid sequence of the light chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the heavy chain of the defucose anti-HER 2 antibody is shown as SEQ ID NO. 3.
2. The use of claim 1, wherein: the amino acid sequence of the light chain of the defucose anti-HER 2 antibody is encoded by the nucleotide sequence shown in SEQ ID NO. 2; the amino acid sequence of the heavy chain of the defucose anti-HER 2 antibody is encoded by the nucleotide sequence shown in SEQ ID NO. 4.
3. Use according to claim 1 or 2, characterized in that: the Fc gamma R2A131R genotype is Fc gamma R2A131R/R genotype or Fc gamma R2A 131R/H genotype.
4. Use according to any one of claims 1 to 3, wherein: the defucose anti-HER 2 antibody comprises a CH2 domain; the amount of fucose in the CH2 domain is zero.
5. The use according to any one of claims 1 to 4, wherein: the defucose anti-HER 2 antibody comprises a glycosyl structure comprising a first glycosyl structure consisting of 3 six carbon sugars and 4N-acetylhexosamine; the proportion of the first glycosyl structure in the glycosyl structure is 60% -95%; the six-carbon sugar comprises one or more of galactose, mannose and glucose; the N-acetylhexosamine includes N-acetylgalactosamine and/or N-acetylglucosamine.
6. The use of claim 5, wherein: the six carbon sugar is mannose; the N-acetylhexosamine is N-acetylglucosamine.
7. The use of claim 5, wherein: the glycosyl structure further comprises a second glycosyl structure, a third glycosyl structure, a fourth glycosyl structure, a fifth glycosyl structure and/or a sixth glycosyl structure; the glycosyl composition of the second glycosyl structure, the third glycosyl structure, the fourth glycosyl structure, the fifth glycosyl structure and the sixth glycosyl structure and the proportion of the glycosyl structures are shown in the following table:
8. the use of claim 7, wherein: sugar chains corresponding to the first, second, third, fourth, fifth and sixth sugar structures are shown in the following table:
Wherein circles in the sugar chain represent the six-carbon sugar; black squares represent the N-acetylglucosamine; black hexagons represent galactose; black circles indicate mannose.
9. Use according to any one of claims 1 to 8, wherein: the cell is a CHO cell, and the knockout is to knock out a gene responsible for encoding fucose, namely FUT8 gene, in the CHO cell by using CRISPR cas9 gene editing technology.
10. Use according to any one of claims 1 to 9, wherein: the patient is HER2 positive; the cancer comprises one or more of breast cancer, esophageal cancer, gastric cancer, lung cancer, bronchial cancer, pancreatic cancer, colon cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, and head and neck cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910356158.5A CN111840544A (en) | 2019-04-29 | 2019-04-29 | Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910356158.5A CN111840544A (en) | 2019-04-29 | 2019-04-29 | Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111840544A true CN111840544A (en) | 2020-10-30 |
Family
ID=72966407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910356158.5A Pending CN111840544A (en) | 2019-04-29 | 2019-04-29 | Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111840544A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023165142A1 (en) * | 2022-03-01 | 2023-09-07 | 苏州智核生物医药科技有限公司 | Her2 binding polypeptide and use thereof |
-
2019
- 2019-04-29 CN CN201910356158.5A patent/CN111840544A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023165142A1 (en) * | 2022-03-01 | 2023-09-07 | 苏州智核生物医药科技有限公司 | Her2 binding polypeptide and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6727379B2 (en) | Bispecific antigen-binding constructs targeting HER2 | |
CN104520327B (en) | Single armed univalent antibody construct and application thereof | |
EP4257611A2 (en) | Anti-muc1 antibody | |
KR20140104944A (en) | Anti-axl antibodies and uses thereof | |
KR20140104945A (en) | Anti-axl antibodies and uses thereof | |
CN107849138B (en) | anti-Aggrus monoclonal antibody and application thereof | |
CN114539411B (en) | ROR1 antibody or antigen binding fragment thereof | |
WO2012020059A1 (en) | Humanized egfr antibodies | |
US20230365653A1 (en) | Tgf-beta rii mutant and fusion protein thereof | |
US20210277139A1 (en) | Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof | |
US10836828B2 (en) | Anti-TREM1 antibodies and related methods | |
CN111840544A (en) | Application of defucose anti-HER 2 antibody in cancer patient carrying Fc gamma R2A131R genotype | |
CA3225092A1 (en) | Cd8-binding polypeptides and uses thereof | |
JP2023526113A (en) | Heterodimeric Fc variants selective for FcgammaRIIB | |
US20210395396A1 (en) | Her2-binding tetrameric polypeptides | |
AU2019358419A1 (en) | HER2-binding tetrameric polypeptides | |
WO2022247905A1 (en) | Anti-cd40 antibody and use thereof | |
KR20130057959A (en) | A fusion monoclonal antibody comprising her2 antibody and il-2, and pharmaceutical composition comprising the same | |
CN111704668B (en) | anti-CCR 4 antibodies and their use in treating cancer | |
US20240238439A1 (en) | Her3-binding antibody-drug conjugate | |
CN118420768A (en) | Anti-HER 2 nanobody multimer, anti-HER 2 nanobody fusion protein, and pharmaceutical composition and application thereof | |
JP2022523145A (en) | Anti-TREM1 antibody and related methods | |
CN115960248A (en) | Dimer fusion protein and application thereof | |
CN114805590A (en) | Bispecific antibodies that bind HER2 | |
CN110563846A (en) | Monoclonal antibody specifically binding to EGFR (epidermal growth factor receptor) and anti-cancer application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201030 |